Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Neurobiol Dis ; 134: 104669, 2020 02.
Article in English | MEDLINE | ID: mdl-31707118

ABSTRACT

Dysfunction of medial prefrontal cortex (mPFC) in association with imbalance of inhibitory and excitatory neurotransmission has been implicated in depression. However, the precise cellular mechanisms underlying this imbalance, particularly for GABAergic transmission in the mPFC, and the link with the rapid acting antidepressant ketamine remains poorly understood. Here we determined the influence of chronic unpredictable stress (CUS), an ethologically validated model of depression, on synaptic markers of GABA neurotransmission, and the influence of a single dose of ketamine on CUS-induced synaptic deficits in mPFC of male rodents. The results demonstrate that CUS decreases GABAergic proteins and the frequency of inhibitory post synaptic currents (IPSCs) of layer V mPFC pyramidal neurons, concomitant with depression-like behaviors. In contrast, a single dose of ketamine can reverse CUS-induced deficits of GABA markers, in conjunction with reversal of CUS-induced depressive-like behaviors. These findings provide further evidence of impairments of GABAergic synapses as key determinants of depressive behavior and highlight ketamine-induced synaptic responses that restore GABA inhibitory, as well as glutamate neurotransmission.


Subject(s)
Antidepressive Agents/administration & dosage , Depression/physiopathology , Ketamine/administration & dosage , Neurons/drug effects , Prefrontal Cortex/drug effects , Stress, Psychological/physiopathology , Synaptic Transmission/drug effects , gamma-Aminobutyric Acid/physiology , Animals , Disease Models, Animal , Inhibitory Postsynaptic Potentials/drug effects , Male , Mice, Inbred C57BL , Neurons/physiology , Prefrontal Cortex/physiopathology
2.
J Clin Invest ; 129(6): 2542-2554, 2019 04 16.
Article in English | MEDLINE | ID: mdl-30990795

ABSTRACT

Preclinical studies demonstrate that rapid acting antidepressants, including ketamine require stimulation of mTORC1 signaling. This pathway is regulated by neuronal activity, endocrine and metabolic signals, notably the amino acid leucine, which activates mTORC1 signaling via binding to the upstream regulator sestrin. Here, we examined the antidepressant actions of NV-5138, a novel highly selective small molecule modulator of sestrin that penetrates the blood brain barrier. The results demonstrate that a single dose of NV-5138 produced rapid and long-lasting antidepressant effects, and rapidly reversed anhedonia caused by chronic stress exposure. The antidepressant actions of NV-5138 required BDNF release as the behavioral responses are blocked by infusion of a BDNF neutralizing antibody into the medial prefrontal cortex (mPFC) or in mice with a knock-in of a BDNF polymorphism that blocks activity dependent BDNF release. NV-5138 administration also rapidly increased synapse number and function in the mPFC, and reversed the synaptic deficits caused by chronic stress. Together, the results demonstrate that NV-5138 produced rapid synaptic and antidepressant behavioral responses via activation of the mTORC1 pathway and BDNF signaling, indicating that pharmacological modulation of sestrin is a novel approach for development of rapid acting antidepressants.


Subject(s)
Antidepressive Agents , Behavior, Animal/drug effects , Heat-Shock Proteins/metabolism , Mechanistic Target of Rapamycin Complex 1/metabolism , Synaptic Transmission/drug effects , Animals , Antidepressive Agents/chemistry , Antidepressive Agents/pharmacokinetics , Antidepressive Agents/pharmacology , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Heat-Shock Proteins/genetics , Male , Mechanistic Target of Rapamycin Complex 1/genetics , Mice , Mice, Knockout , Rats , Rats, Sprague-Dawley , Synaptic Transmission/genetics
3.
Biol Psychiatry ; 83(1): 38-49, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-28697890

ABSTRACT

BACKGROUND: Chronic stress exposure causes neuronal atrophy and synaptic deficits in the medial prefrontal cortex (PFC), contributing to development of anxiety- and depressive-like behaviors. Concomitantly, microglia in the PFC undergo morphological and functional changes following stress exposure, suggesting that microglia contribute to synaptic deficits underlying behavioral consequences. METHODS: Male and female mice were exposed to chronic unpredictable stress (CUS) to examine the role of neuron-microglia interactions in the medial PFC during development of anxiety- and depressive-like behaviors. Thy1-GFP-M mice were used to assess microglia-mediated neuronal remodeling and dendritic spine density in the medial PFC. Viral-mediated knockdown of neuronal colony stimulating factor 1 (CSF1) was used to modulate microglia function and behavioral consequences after CUS. RESULTS: CUS promoted anxiety- and depressive-like behaviors that were associated with increased messenger RNA levels of CSF1 in the PFC. Increased CSF1 messenger RNA levels were also detected in the postmortem dorsolateral PFC of individuals with depression. Moreover, microglia isolated from the frontal cortex of mice exposed to CUS show elevated CSF1 receptor expression and increased phagocytosis of neuronal elements. Notably, functional alterations in microglia were more pronounced in male mice compared with female mice. These functional changes in microglia corresponded with reduced dendritic spine density on pyramidal neurons in layer 1 of the medial PFC. Viral-mediated knockdown of neuronal CSF1 in the medial PFC attenuated microglia-mediated neuronal remodeling and prevented behavioral deficits caused by CUS. CONCLUSIONS: These findings revealed that stress-induced elevations in neuronal CSF1 provokes microglia-mediated neuronal remodeling in the medial PFC, contributing to synaptic deficits and development of anxiety- and depressive-like behavior.


Subject(s)
Depressive Disorder/metabolism , Macrophage Colony-Stimulating Factor/metabolism , Microglia/metabolism , Neuronal Plasticity/physiology , Neurons/metabolism , Stress, Psychological/metabolism , Animals , Anxiety/metabolism , Anxiety/pathology , Chronic Disease , Depressive Disorder/pathology , Disease Models, Animal , Female , Macrophage Colony-Stimulating Factor/genetics , Male , Mice, Inbred C57BL , Mice, Transgenic , Microglia/pathology , Neurons/pathology , Phagocytosis/physiology , Prefrontal Cortex/metabolism , Prefrontal Cortex/pathology , RNA, Messenger/metabolism , Receptor, Macrophage Colony-Stimulating Factor/metabolism , Sex Characteristics , Stress, Psychological/pathology , Uncertainty
4.
J Neurochem ; 113(1): 175-87, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20070867

ABSTRACT

The molecular mechanism of action of antipsychotic drugs is not well understood. Their complex receptor affinity profiles indicate that their action could extend beyond dopamine receptor blockade. Single gene expression studies and high-throughput gene profiling have shown the induction of genes from several molecular classes and functional categories. Using a focused microarray approach, we investigated gene regulation in rat striatum, frontal cortex, and hippocampus after chronic administration of haloperidol or olanzapine. Regulated genes were validated by in situ hybridization, real-time PCR, and immunohistochemistry. Only limited overlap was observed in genes regulated by haloperidol and olanzapine. Both drugs elicited maximal gene regulation in the striatum and least in the hippocampus. Striatal gene induction by haloperidol was predominantly in neurotransmitter signaling, G-protein coupled receptors, and transcription factors. Olanzapine prominently induced retinoic acid and trophic factor signaling genes in the frontal cortex. The data also revealed the induction of several genes that could be targeted in future drug development efforts. The study uncovered the induction of several novel genes, including somatostatin receptors and metabotropic glutamate receptors. The results demonstrating the regulation of multiple receptors and transcription factors suggests that both typical and atypical antipsychotics could possess a complex molecular mechanism of action.


Subject(s)
Antipsychotic Agents/pharmacology , Benzodiazepines/pharmacology , Brain/drug effects , Gene Expression Regulation/drug effects , Haloperidol/analogs & derivatives , Animals , Brain/metabolism , Gene Expression Profiling/methods , Haloperidol/pharmacology , Male , Neurotransmitter Agents/genetics , Neurotransmitter Agents/metabolism , Olanzapine , Oligonucleotide Array Sequence Analysis/methods , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/metabolism , Signal Transduction/drug effects , Signal Transduction/genetics , Transcription Factors/genetics , Transcription Factors/metabolism
5.
Behav Brain Res ; 198(2): 366-71, 2009 Mar 17.
Article in English | MEDLINE | ID: mdl-19056428

ABSTRACT

Growth factors in the brain are important to depression and it's treatment and we assessed the ability of peripherally administered insulin-like growth factor-I (IGF-I) to influence behavior related to depression. We found that mice that received chronic IGF-I treatment showed antidepressant-like behavior in forced-swim and novelty-induced hypophagia (NIH) tests and increased sucrose consumption after chronic mild unpredictable stress exposure. Additionally, peripheral anti-IGF-I administration blocked exercise-induced antidepressant effects in the forced-swim test (FST). These results support the functional relevance of neurotrophic mechanisms to depression and extend this idea to include neurotrophic factors in the periphery.


Subject(s)
Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Depression/drug therapy , Insulin-Like Growth Factor I/physiology , Stress, Physiological/drug effects , Animals , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Depression/psychology , Enzyme-Linked Immunosorbent Assay , Exercise/psychology , Humans , Immunoglobulin G/pharmacology , In Situ Hybridization , Injections, Subcutaneous , Insulin-Like Growth Factor I/administration & dosage , Insulin-Like Growth Factor I/antagonists & inhibitors , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor I/pharmacology , Male , Mice , Motor Activity/physiology , Swimming/physiology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...